Drug Profile


Alternative Names: MCAF-5352A; NI-1401; NI-1401/α-IL-17; RG-7624

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovImmune SA
  • Developer Genentech
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation
  • Discontinued Autoimmune disorders

Most Recent Events

  • 05 Sep 2016 Phase-I clinical trials in Inflammation in USA (Unspecified) before September 2016
  • 28 Jan 2015 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in Canada (SC)
  • 12 Mar 2013 Genentech completes a phase Ib trial in Autoimmune disorders (in volunteers) in Canada (NCT01540760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top